These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27221667)

  • 1. Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management.
    Chanprapaph K; Rutnin S; Vachiramon V
    Am J Clin Dermatol; 2016 Aug; 17(4):387-402. PubMed ID: 27221667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).
    Anderson R; Jatoi A; Robert C; Wood LS; Keating KN; Lacouture ME
    Oncologist; 2009 Mar; 14(3):291-302. PubMed ID: 19276294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hand-foot syndrome after administration of tyrosinkinase inhibitors].
    Bednaríková D; Kocák I
    Klin Onkol; 2010; 23(5):300-5. PubMed ID: 21061680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
    McLellan B; Kerr H
    Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lacouture ME; Wu S; Robert C; Atkins MB; Kong HH; Guitart J; Garbe C; Hauschild A; Puzanov I; Alexandrescu DT; Anderson RT; Wood L; Dutcher JP
    Oncologist; 2008 Sep; 13(9):1001-11. PubMed ID: 18779536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
    Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
    Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe sorafenib-induced hand-foot skin reaction.
    Cuesta L; Betlloch I; Toledo F; Latorre N; Monteagudo A
    Dermatol Online J; 2011 May; 17(5):14. PubMed ID: 21635836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J; Escudier B; Wechsler J; Spatz A; Robert C
    Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interstitial granulomatous drug reaction to sorafenib.
    Martínez-Morán C; Nájera L; Ruiz-Casado AI; Romero-Maté A; Espinosa P; Meseguer-Yebra C; Córdoba S; Borbujo JM
    Arch Dermatol; 2011 Sep; 147(9):1118-9. PubMed ID: 21931061
    [No Abstract]   [Full Text] [Related]  

  • 11. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
    Lipworth AD; Robert C; Zhu AX
    Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib.
    Wolber C; Udvardi A; Tatzreiter G; Schneeberger A; Volc-Platzer B
    J Dtsch Dermatol Ges; 2009 May; 7(5):449-52. PubMed ID: 19178612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction.
    Jain L; Gardner ER; Figg WD; Chernick MS; Kong HH
    Pharmacotherapy; 2010 Jan; 30(1):52-6. PubMed ID: 20030473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hand-foot-syndrome associated with medical tumor therapy - classification and management.
    Degen A; Alter M; Schenck F; Satzger I; Völker B; Kapp A; Gutzmer R
    J Dtsch Dermatol Ges; 2010 Sep; 8(9):652-61. PubMed ID: 20482685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis.
    Zhu Y; Zhang X; Lou X; Chen M; Luo P; He Q
    Clin Exp Pharmacol Physiol; 2018 Jul; 45(7):659-667. PubMed ID: 29543385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Palmoplantar cutaneous reaction to sorafenib].
    Echeverría B; Llombart B; Botella-Estrada R; Guillén C
    Actas Dermosifiliogr; 2009 Oct; 100(8):736-7. PubMed ID: 19775561
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.
    Manchen E; Robert C; Porta C
    J Support Oncol; 2011; 9(1):13-23. PubMed ID: 21465734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer chemotherapy and skin changes.
    Vogelzang NJ; Ratain MJ
    Ann Intern Med; 1985 Aug; 103(2):303-4. PubMed ID: 3160276
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma.
    Hütten M; Lassay L; Sachs B; Deutz P; Mertens R; Baron JM; Merk HF; Ott H
    Pediatr Dermatol; 2009; 26(3):349-50. PubMed ID: 19706105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
    Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
    Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.